Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announcedWednesday that it has agreed with American Cyanamid Co.(NYSE:ACY) to develop and market two new neurotrophicfactors, heparin binding neurotrophic factor (HBNF) andmidkine (MK).

The two companies will co-promote any products resultingfrom the collaboration and share the profits equally.

Cyanamid of Wayne, N.J., received a U.S. patent, No. 5,171,842,on HBNF on Tuesday.

Regeneron of Tarrytown, N.Y., is currently developing ciliaryneurotrophic factor for treating Lou Gehrig's disease (ALS), andis collaborating with Amgen Inc. to develop and commercializebrain-derived neurotrophic factor and neurotrophin-3 fortreating neuropathies, motor neuron diseases and retinaldegenerations

(c) 1997 American Health Consultants. All rights reserved.